S. Vukelja

发表

Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer.

N. Senzer, J. Nemunaitis, M. Cheever, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

David Miles, Shailendra Verma, Chris Twelves, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.

B. Erikstein, S. Verma, D. Miles, 2001 .

Phase 1 study of escalating-dose OncoGel® (ReGel®/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions

J. Nemunaitis, W. Samlowski, J. Arseneau, 2007, Anti-cancer drugs.

Mean platelet volume improves upon the megathrombocyte index but cannot replace the blood film examination in the evaluation of thrombocytopenia

S. Vukelja, L. Diehl, J. Krishnan, 1993, American journal of hematology.

Phase I Trial of PT-100 (PT-100), A Cytokine-Inducing Small Molecule, Following Chemotherapy for Solid Tumor Malignancy

N. Senzer, J. Nemunaitis, C. Cunningham, 2006, Cancer investigation.

Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br

H. Gómez, N. Robert, C. Geyer, 2016 .

Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC)

D. Miles, L. Mauriac, J. O’Shaughnessy, 2001 .

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

J. O’Shaughnessy, J. Goldschmidt, J. Blum, 2019, npj Breast Cancer.

Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.

T. Cartwright, A. Cohn, S. Vukelja, 2008, Clinical colorectal cancer.

Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.

J. O’Shaughnessy, M. Orlando, S. Vukelja, 2008, Clinical breast cancer.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

J. Baselga, G. Sledge, K. Blackwell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Eosinophilia associated with adult t‐cell leukemia/lymphoma

D. Longo, R. Weiss, S. Vukelja, 1988, Cancer.

Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer

J. Pippen, S. Vukelja, J. Iglesias, 2011, Breast Cancer Research and Treatment.

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days1, 3, and 5 Every 3 Weeks in Patientswith Advanced Solid Tumors

P. Bonate, D. Ryan, L. Appleman, 2005 .

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

P. Bonate, D. Ryan, L. Appleman, 2005, Clinical Cancer Research.

Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium

S. Awasthi, W. Berry, Thomas E. Hutson, 2008, Investigational New Drugs.

Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.

J. O’Shaughnessy, J. Pippen, S. Vukelja, 2002, Clinical breast cancer.

Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results

E. Perez, L. Denis, P. Mainwaring, 2005 .

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

K. Kolibaba, R. Taetle, S. Vukelja, 2008, Blood.

Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.

P. LoRusso, L. Amler, H. Burris, 2010 .

Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis.

S. Vukelja, B. Alving, C. Krishnamurti, 1994, Thrombosis research.

Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.

E. Dees, J. O’Shaughnessy, J. Blum, 2007, Clinical Breast Cancer.

Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?

J. O’Shaughnessy, C. Twelves, A. Bexon, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial.

D. Miles, L. Mauriac, J. O’Shaughnessy, 2004, Clinical Breast Cancer.

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

F. Holmes, J. O’Shaughnessy, J. Pippen, 2010 .

Azathioprine as a steroid-sparing agent in radiation pneumonitis.

S. Vukelja, P. Lillis, M. McCarty, 1996, Chest.

Nonbacterial Thrombotic Endocarditis Clinically Mimicking Veno‐Occlusive Disease of the Liver Complicating Autologous Bone Marrow Transplantation

S. Vukelja, W. Baker, P. Jeffreys, 1992, American journal of clinical oncology.

Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.

S. Papish, P. Fox, F. Holmes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel-induced radiation recall dermatitis.

S. Vukelja, M. Peake, P. Lillis, 1996, Medical and pediatric oncology.

Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.

M. Burotto, L. Fallowfield, S. Margolin, 2021, European journal of cancer.

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients

J. O’Shaughnessy, S. Vukelja, J. W. Smith, 2013, Breast Cancer Research and Treatment.

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphomatoid papulosis associated with Ki‐1‐positive anaplastic large cell lymphoma. A report of two cases and a review of the literature

E. Jaffe, E. Sausville, R. Weiss, 1994, Cancer.

Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea

S. Vukelja, T. O'rourke, J. Furgerson, 1996, American journal of hematology.

Pyroxidine for the Palmar-Plantar Erythrodysesthesia Syndrome

R. Weiss, W. James, S. Vukelja, 1989 .

Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil.

S. Vukelja, J. Keeling, M. Mccollough, 1991, Journal of the American Academy of Dermatology.

Pyridoxine for the palmar-plantar erythrodysesthesia syndrome.

R. Weiss, W. James, S. Vukelja, 1989, Annals of internal medicine.

Angiofollicular lymph node hyperplasia (Castleman's disease).

P. Banks, R. Weiss, S. Vukelja, 1995, Cancer treatment reviews.

A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer

J. Hainsworth, N. Robert, J. O’Shaughnessy, 2007 .

Hypercoagulable states. Their causes and management.

S. Vukelja, K. Bowen, Karen J. Bowen, 1992, Postgraduate medicine.

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.

D. V. Von Hoff, H. Burris, S. Vukelja, 1993, Journal of the National Cancer Institute.

Diffuse alveolar hemorrhage following autologous bone marrow infusion.

S. Vukelja, D. Wiener, W. Baker, 1993, Bone marrow transplantation.

A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study

J. O’Shaughnessy, J. Pippen, Stephen E. Jones, 2004 .

Cutaneous pigmentation after daunorubicin chemotherapy.

T. Berger, S. Vukelja, L. Anderson, 1992, Journal of the American Academy of Dermatology.

Idarubicin-induced pigmentary changes of the nails.

S. Vukelja, J. Keeling, D. Borecky, 1997, Cutis.

Chemotherapy of Disseminated Merkel‐Cell Carcinoma

N. Dawson, S. Vukelja, J. Iii, 1991, American journal of clinical oncology.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

H. Rugo, L. Amler, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

J. Baselga, M. Casey, G. Sledge, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer.

J. Hainsworth, N. Robert, N. Senzer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemophagocytic syndrome: A cause of pancytopenia in human ehrlichiosis

K. Abbott, S. Vukelja, T. O'rourke, 1991, American journal of hematology.

Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer

J. O’Shaughnessy, S. Vukelja, D. Weckstein, 2007 .

Resolution of pure red cell aplasia and lymphoma: Response to intravenous gammaglobulin and combination chemotherapy

S. Vukelja, A. Salvado, J. Krishnan, 1989, American journal of hematology.

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Lajos Pusztai, Christos Sotiriou, Kenneth R Hess, 2007, The Lancet. Oncology.

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

N. Robert, F. Holmes, J. O’Shaughnessy, 2013, The Lancet. Oncology.

Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients

J. O’Shaughnessy, J. Goldschmidt, J. Blum, 2019, npj Breast Cancer.

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

J. O’Shaughnessy, J. Blum, S. Vukelja, 2011 .

Atypical medullary carcinoma of the breast metastatic to the oral cavity.

S. Vukelja, S J Vukelja, M J McCarty, 1994, American journal of otolaryngology.

Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer

F. Holmes, J. O’Shaughnessy, B. Hellerstedt, 2018, Cancer medicine.

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

D. Royall, D. V. Von Hoff, F. Holmes, 2005, Clinical breast cancer.

Testicular relapse in adult acute lymphocytic leukemia: a case report and literature review.

S. Swanson, R. Weiss, S. Vukelja, 1989, Medical and pediatric oncology.

A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.

M. Birkner, H. Burris, C. Vogel, 2009 .

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

H. Gómez, N. Robert, C. Geyer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

H. Koeppen, F. Holmes, J. O’Shaughnessy, 2015, Clinical Cancer Research.

Postoperative toxic shock syndrome: a case report and review of the literature.

S. Vukelja, G. Yelland, M. Molloy, 1989, Military medicine.

Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).

J. Nemunaitis, R. Hermann, J. Bendell, 2010 .

Effect of clofarabine on lymphocyte populations in patients treated for solid tumors

N. Senzer, J. Nemunaitis, R. Abichandani, 2007 .

Gilbert's syndrome co-existing with and masking hereditary spherocytosis

S. Vukelja, S. Kadakia, Sunil Sharma, 1997, Annals of Hematology.

The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer

F. Holmes, J. O’Shaughnessy, M. Kasper, 2009, Breast Cancer Research and Treatment.

A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study.

J. O’Shaughnessy, J. Pippen, S. Jones, 2004, Journal of Clinical Oncology.

Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study

N. Senzer, J. Nemunaitis, C. Cunningham, 2004 .

Clofarabine administered weekly to adult patients with advanced solid tumors in a phase I dose-finding study.

N. Senzer, J. Nemunaitis, C. Cunningham, 2004, Journal of Clinical Oncology.

Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC).

P. LoRusso, M. Beeram, S. Girish, 2009 .

5020 Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results

H. Rugo, M. Sliwkowski, H. Burris, 2009 .

A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.

M. Birkner, H. Burris, C. Vogel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer

J. O’Shaughnessy, J. Pippen, Stephen E. Jones, 2005 .

A planned comparison of menopausal symptoms during year 1 in patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study

J. Pippen, S. Jones, J. Blum, 2003 .

A dose-escalation, Phase I study of a depot formulation of paclitaxel administered intralesionally in end-stage cancer patients with solid malignant tumors.

J. Nemunaitis, W. Samlowski, J. Arseneau, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High‐Dose Taxol, Cyclophosphamide, and Cisplatin with Stem Cell Support in the Treatment of Metastatic Breast Cancer

J. Stephenson, S. Vukelja, M. Atkins, 1998 .

Severe dermatologic Toxocity from 5‐Fluorouracil in the Presence of Seborrheic dermatitis

W D James, R. Weiss, W. James, 1989, International journal of dermatology.

Preliminary Toxicity Results of a Phase II Randomized Trial of Weekly or Every 3-Week Ixabepilone in Metastatic Breast Cancer (MBC).

J. O’Shaughnessy, S. Vukelja, L. Asmar, 2009 .

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

L. R. Hill, F. Holmes, J. O’Shaughnessy, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer.

J. O’Shaughnessy, S. Vukelja, James X. Song, 2016, Clinical breast cancer.

Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.

T. Cartwright, S. Vukelja, L. Asmar, 2005, Clinical colorectal cancer.

Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy

F. Holmes, J. O’Shaughnessy, N. Wu, 2013 .

A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.

W. Edenfield, F. Braiteh, C. Li, 2016 .

Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer

Simin Hu, S. Vukelja, D. Richards, 2011, Investigational New Drugs.

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.

T. Cartwright, S. Vukelja, L. Asmar, 2004, Journal of Clinical Oncology.

Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).

F. Holmes, J. O’Shaughnessy, S. Vukelja, 2012 .

Erythropoietin in the treatment of iron overload in a patient with hemolytic anemia and pyruvate kinase deficiency.

S. Vukelja, 1994, Acta haematologica.